Prospective pulmonary drug delivery system of pirfenidone microparticles for pulmonary fibrosis

Orally administered pirfenidone in pulmonary fibrosis therapy induces numerous systemic adverse effects. This study aims to develop pirfenidone microparticles for pulmonary delivery to reduce the systemic adverse effects of pirfenidone. Ten formulations of pirfenidone microparticles were prepared using the spray drying method, including sodium carboxymethyl cellulose and sodium alginate as polymers, ammonium bicarbonate as porogen, and L-leucine as dispersing agent. These microparticles were evaluated using physicochemical characterization, stability, and in vitro cytotoxicity studies. The F10 formulation, which consisted of sodium alginate 1.0%, ammonium bicarbonate 0.3%, and L-leucine 0.4%, had the most relevant results for inhalation. The mass median aerodynamic diameters (MMADs) of F10 were 0.065, 0.597, 2.212, and 5.626 µm, ideal for deposition in the bronchiolar to the alveolar region. The stability study showed that the pirfenidone contents were 99.08%–100.00% and 98.83%–100.00%, with an increasing MMAD up to 5.895 and 6.273 µm at 30°C ± 2°C and 40°C ± 2°C, respectively. The in vitro cytotoxicity study revealed that the pulmonary epithelial cells (A549 cells) were less sensitive to the excipients in the formulation than pirfenidone ( p = 0.018). Furthermore, F10 caused significantly lower interleukin-6 release than pirfenidone ( p < 0.05). In conclusion, F10 shows suitable characteristics for pulmonary pirfenidone delivery in pulmonary fibrosis therapy.

[1]  A. Gutleb,et al.  Maximizing the relevance and reproducibility of A549 cell culture using FBS-free media. , 2022, Toxicology in vitro : an international journal published in association with BIBRA.

[2]  Silvia Surini,et al.  Promising chitosan-alginate combination for rifampicin dry powder inhaler to target active and latent tuberculosis , 2022, Journal of Applied Pharmaceutical Science.

[3]  F. Kakamad,et al.  Post COVID-19 pulmonary fibrosis; a meta-analysis study , 2022, Annals of Medicine and Surgery.

[4]  M. Yacoub,et al.  Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective , 2021, Nature Reviews Cardiology.

[5]  J. Gawałek.  Effect of Spray Dryer Scale Size on the Properties of Dried Beetroot Juice , 2021, Molecules.

[6]  Guilan Quan,et al.  Effects of L-leucine on the properties of spray-dried swellable microparticles with wrinkled surfaces for inhalation therapy of pulmonary fibrosis. , 2021, International journal of pharmaceutics.

[7]  V. Nebolsin,et al.  Lung Fibrosis after COVID-19: Treatment Prospects , 2021, Pharmaceuticals.

[8]  X. Tang,et al.  Role of interleukins in the pathogenesis of pulmonary fibrosis , 2021, Cell death discovery.

[9]  Niall J. O'Reilly,et al.  Designing enhanced spray dried particles for inhalation: A review of the impact of excipients and processing parameters on particle properties , 2021 .

[10]  A. Mahmoud,et al.  Formulation and optimization of sildenafil citrate-loaded PLGA large porous microparticles using spray freeze-drying technique: A factorial design and in-vivo pharmacokinetic study. , 2021, International journal of pharmaceutics.

[11]  Birendra Chaurasiya,et al.  Dry Powder for Pulmonary Delivery: A Comprehensive Review , 2020, Pharmaceutics.

[12]  Mark G. Jones,et al.  Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. , 2020, Pharmacology & therapeutics.

[13]  A. Mujumdar,et al.  Preparation and characterization of sustained release pirfenidone loaded microparticles for pulmonary drug delivery: Spray drying approach , 2020, Drying Technology.

[14]  Yasuhiro Abe,et al.  Relationship Between Geometric and Aerodynamic Particle Size Distributions in the Formulation of Solution and Suspension Metered-Dose Inhalers , 2020, AAPS PharmSciTech.

[15]  Silvia Surini,et al.  STABILITY STUDY OF ETHYLCELLULOSE COATED-TOCOTRIENOL MICROCAPSULES PREPARED BY SOLVENT EVAPORATION AND SPRAY DRYING TECHNIQUES , 2020, International Journal of Applied Pharmaceutics.

[16]  R. Aquino,et al.  Design and Development of Spray-Dried Microsystems to Improve Technological and Functional Properties of Bioactive Compounds from Hazelnut Shells , 2020, Molecules.

[17]  I. Glaspole,et al.  A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis , 2020, Journal of aerosol medicine and pulmonary drug delivery.

[18]  P. Bardin,et al.  Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease. , 2020, American journal of respiratory cell and molecular biology.

[19]  V. Bucalá,et al.  A Review on Influence of Spray Drying Process Parameters on the Production of Medicinal Plant Powders. , 2019, Current drug discovery technologies.

[20]  A. Mahmoud,et al.  Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[21]  R. Ambrus,et al.  Formulation and comparison of spray dried non‐porous and large porous particles containing meloxicam for pulmonary drug delivery , 2019, International journal of pharmaceutics.

[22]  Silvia Surini,et al.  Formula Optimization of Rifampicin Dry Powder Inhalation with Chitosan-Xanthan Carrier Using Response Surface Methodology , 2019, Journal of Applied Pharmaceutical Science.

[23]  Silvia Surini,et al.  MICROENCAPSULATION OF GRAPE SEED OIL (VITIS VINIFERA L.) WITH GUM ARABIC AS A COATING POLYMER BY CROSSLINKING EMULSIFICATION METHOD , 2018, International Journal of Applied Pharmaceutics.

[24]  A. Mahmoud,et al.  Design and characterization of emulsified spray dried alginate microparticles as a carrier for the dually acting drug roflumilast , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[25]  J. Stauffer,et al.  Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis , 2017, European Respiratory Review.

[26]  V. Bucalá,et al.  Formulation and Characterization of Polysaccharide Microparticles for Pulmonary Delivery of Sodium Cromoglycate , 2016, AAPS PharmSciTech.

[27]  J. Zhao,et al.  Exploring polyvinylpyrrolidone in the engineering of large porous PLGA microparticles via single emulsion method with tunable sustained release in the lung: In vitro and in vivo characterization , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Ha Ryong Kim,et al.  In vitro inflammatory effects of polyhexamethylene biguanide through NF-κB activation in A549 cells. , 2017, Toxicology in vitro : an international journal published in association with BIBRA.

[29]  Samantha A. Meenach,et al.  In Vitro Pulmonary Cell Culture in Pharmaceutical Inhalation Aerosol Delivery: 2-D, 3-D, and In Situ Bioimpactor Models. , 2016, Current pharmaceutical design.

[30]  A. Healy,et al.  Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate. , 2016, International journal of pharmaceutics.

[31]  G. Raghu,et al.  Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis. , 2016, Chest.

[32]  P. Seville,et al.  Influence of excipients on spray-dried powders for inhalation , 2014 .

[33]  S. Onoue,et al.  Inhalable Powder Formulation of Pirfenidone with Reduced Phototoxic Risk for Treatment of Pulmonary Fibrosis , 2013, Pharmaceutical Research.

[34]  F. Ungaro,et al.  Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[35]  V. Nekkanti,et al.  Spray-drying process optimization for manufacture of drug–cyclodextrin complex powder using design of experiments , 2009, Drug development and industrial pharmacy.

[36]  Silvia Surini,et al.  Study of mucoadhesive microspheres based on pregelatinized cassava starch succinate as a new carrier for drug delivery , 2009 .

[37]  G. Soma,et al.  Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[38]  David B Warheit,et al.  Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[39]  V. Cottin.  [Treatment of pulmonary fibrosis]. , 2002, Presse medicale.

[40]  R. Langer,et al.  Recent advances in pulmonary drug delivery using large, porous inhaled particles. , 1998, Journal of applied physiology.

[41]  Y Ikada,et al.  Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. , 1988, Biomaterials.

[42]  S. Rosselot.  Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[43]  B. Mishra,et al.  Formulation optimization and characterization of spray dried microparticles for inhalation delivery of doxycycline hyclate. , 2011, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[44]  C. Kuhn.  The pathogenesis of pulmonary fibrosis. , 1993, Monographs in pathology.